Ambient voice technology enters its scale-up phase

AVT remains a rapidly evolving category where different suppliers are pursuing different approaches to clinical safety, workflow integration, deployment models and AI architecture. The competitive landscape for this market is substantial, with the latest signal coming from Australian company, Heidi.

Interested in learning more about investment for healthtech innovation? Sign up to the HIN Investment Update.

The race to transform clinical documentation through ambient voice technology (AVT) has moved decisively into a new phase. What began as a collection of NHS pilots and clinician-led experiments is increasingly becoming a market defined by enterprise deployments, significant capital investment and platform ambitions extending well beyond note generation. The latest signal came from Australia’s Heidi, which announced $340 million in new funding in October, including a $100 million Series C and $240 million growth investment – bringing the total business value to $900 million.

For investors and founders, the significance is not simply the size of the round. It is what the capital is being deployed to achieve. Like several leaders in the category, Heidi is moving from ambient documentation towards broader workflow automation, developing supervised AI agents capable of tasks such as drafting referrals, preparing records ahead of consultations and supporting clinical workflows, while keeping clinicians in control of final decisions.

The competitive landscape is already substantial. NHS England’s AVT registry includes 30 suppliers, ranging from Heidi to venture-backed specialists such as Tandem, DigitalHealth.London Accelerator alumni Tortus and established healthcare IT incumbents including Microsoft Dragon, Optum and others.

Far from being a sign of market fragmentation, this diversity should be viewed as a strength.

Competition is driving innovation

Healthcare technology markets often benefit from periods of intense competition before long-term winners emerge. AVT remains a rapidly evolving category where different suppliers are pursuing different approaches to clinical safety, workflow integration, deployment models and AI architecture.

Industry analysis from The King’s Fund argues that AVT presents a rare opportunity not only to reduce administrative burden and improve working conditions for clinicians, but also to stimulate a thriving supplier ecosystem and strengthen the UK’s AI capability. The report specifically warns against concentrating benefits in isolated deployments and highlights the importance of building a vibrant marketplace of suppliers.

This mirrors what is already happening in practice. NHS organisations continue to trial a range of solutions across multiple settings, from outpatient clinics to ambulance services and emergency departments. In south west London, the Health Innovation Network South London is supporting a group of providers on an ambitious multi-year procurement and implementation exercise which will give thousands of clinicians access to AVT.  Barts Health has announced plans to deploy AVT at scale after pilot results demonstrated improvements in consultation quality and time savings for clinicians, while Oxford University Hospitals reported that almost 90% of clinicians experienced reduced documentation time during pilots.

For investors, that level of adoption provides increasing evidence that AVT is moving from experimentation into operational infrastructure.

Scale is becoming the differentiator

While Heidi’s fundraising has attracted significant attention, it is far from the only company demonstrating momentum.

Tandem Health recently raised a $100 million Series B, led by EQT’s Scaleup Europe Fund, bringing total funding to $160 million. The company reports deployment across more than 10,000 care organisations in 14 European markets and has articulated an ambition to evolve from an AI medical assistant into an AI-native clinic operating system.

Its partnership with Accurx provides one of the strongest examples of how distribution can accelerate adoption. Since Accurx was on the DigitalHealth.London Accelerator in 2016, its communications platform now being used by 98% of GP practices in England and more than 200,000 NHS staff. Through the “Accurx Scribe, powered by Tandem” partnership, the companies have secured 25 trust-wide contracts and major deployments including a four-year programme across University Hospitals of Leicester and University Hospitals of Northamptonshire covering approximately 10,000 clinicians.

Meanwhile, UK-founded Tortus AI, one of the most recognised names in the sector, continues to expand through large-scale NHS evaluations and deployments. Its technology has been tested across thousands of patient interactions, including NHS England-supported pilots assessing impact on productivity and clinician workload

Accurx, itself another NHS innovation success story, has demonstrated how existing clinical workflow platforms can leverage trusted relationships and deep NHS integration to accelerate adoption of new AI capabilities.

The bigger opportunity

Perhaps the most important takeaway for founders and investors is that the market is no longer fundamentally about transcription.

The leading vendors are increasingly positioning themselves around workflow automation, clinical decision support, coding, referrals, patient communications and administrative orchestration. The ambition is not merely to save clinicians a few minutes per appointment, but to create AI-enabled operating systems for healthcare delivery.

Yet with that ambition comes uncertainty. Clinical safety standards, regulatory frameworks, integration requirements and procurement models continue to evolve. No single company has yet established an unassailable position.

That is precisely why strong competition remains valuable. With 30 suppliers on the NHS registry and multiple approaches being tested in real-world settings, the NHS is in a position to evaluate what works, what scales and what delivers measurable value. If the NHS were to consolidate on a few suppliers at this time it would reduce the investment in developing and refining the current fast-evolving solutions.   For investors, Heidi’s landmark financing and Tandem’s substantial raise suggest growing confidence that AVT represents one of the most compelling AI categories in healthcare. For entrepreneurs, the message is equally clear: the market opportunity remains significant, but winning will require more than a good scribe. The next generation of leaders will be those that turn documentation into workflow, workflow into productivity, and productivity into demonstrable outcomes for patients, clinicians and health systems alike.

Subscribe to the HIN Investment Update for key investment news, exclusive insights from the HIN’s investor network, and the latest opportunities and events. Ideal for growing healthtech companies, as well as funders and investors shaping the health innovation ecosystem.